General
Preferred name
DIPRAGLURANT
Synonyms
ADX48621 ()
ADX-48621 ()
P&D ID
PD051953
CAS
872363-17-2
Tags
available
drug candidate
Drug indication
Mood disorder
Dyskinesia
Parkinson disease
Drug Status
investigational
Max Phase
2.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Dipraglurant (ADX48621) is a potent, selective, orally active and brain penetrant mGluR5 negative allosteric modulator (NAM), with an IC50 of 21 nM. Dipraglurant can reduce Levodopa-induced dyskinesia (LID) in vivo[1][2]. Dipraglurant is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
PRICE 245
DESCRIPTION Dipraglurant is a mGlu5 receptor negative allosteric modulator. It is currently in phase II for the treatment of dyskinesia in Parkinson's disease. (BOC Sciences Bioactive Compounds)
DESCRIPTION Dipraglurant (ADX48621) is a negative alteration modulator (NAM) of mGluR5 that inhibits dyskinesia in the LID macaque model. (TargetMol Bioactive Compound Library)
Compound Sets
11
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugMAP
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
ReFrame library
TargetMol Bioactive Compound Library
External IDs
24
Properties
(calculated by RDKit )
Molecular Weight
265.1
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
0
Rotatable Bonds
2
Ring Count
3
Aromatic Ring Count
3
cLogP
2.85
TPSA
30.19
Fraction CSP3
0.12
Chiral centers
0.0
Largest ring
6.0
QED
0.67
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
mGluR5
GRM5
mGluR
MOA
glutamate receptor negative allosteric modulator
Pathway
Neuroscience
GPCR/G protein
Neuronal Signaling
Source data